It seems that the do-all, fix-all, be-all for kidney problems is either an ARB or ACE-I. We start patients on these medications at the first sign of elevated glucose levels regardless of their blood pressure levels, as they “protect” the kidneys. This is definitely true, but what do we do …

This patient was newly diagnosed, but I did not really think she believed she had diabetes. In other words, she was in denial. Once she saw the results of her labs, I could see things changed in her. She “got it."

In part 1 of this Exclusive Interview, Michael Hill discusses the release of the hybrid closed-loop system, the Minimed 670G.

In this week's Homerun Slides, therapeutic approaches for chronic kidney disease beyond Renin-angiotensin system (RAS) blockade.

Gluconeogenic pathways: Gluconeogenesis is the synthesis of glucose from three carbon precursors such as alanine, pyruvate, lactate, and glycerol and is essentially a reversal of glycolysis. Under normal conditions, 90% of gluconeogenesis occurs in liver, and the rest occurs mainly in the renal cortex. Other sites of gluconeogenesis, such as the small intestine have been suggested but remain controversial.